Patents by Inventor Yasuhiro Furuichi
Yasuhiro Furuichi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230323355Abstract: Described herein are antiviral silencing RNA molecules (siRNAs), pharmaceutical compositions comprising same and uses thereof for the treatment of viral infections. In embodiments the siRNAs comprises chemically modification(s) for enhanced cell penetrating abilities and/or for greater nuclease resistance. Examples of chemical modifications include substituting one or more nucleotides of a native siRNA molecule with 2?-O-Methylnucleoside, 2?-Fluoronucleoside, aminoalkyl-nucleotide, aminoethyl-nucleotide, and/or 5?-aminopropyl-2?-OMe-nucleoside. The chemically modified nucleotides may be incorporated into the P strand, the G strand or both. Other possible modifications include coupling a compound such as a spermine molecule to the 5? terminus or the 3? terminus of the siRNA.Type: ApplicationFiled: September 3, 2021Publication date: October 12, 2023Applicant: SOLSTAR PHARMA INC.Inventors: Dionissios BALTZIS, Yasuhiro FURUICHI, Tokuhiro CHANO, Yoshihito UENO, Kumiko UI-TEI, Max ARELLA
-
Patent number: 10548990Abstract: Double-stranded modified siRNA targeting a RecQL1 helicase gene includes a sense strand including the nucleotide sequence shown in SEQ ID NO: 1, and an antisense strand including the nucleotide sequence shown in SEQ ID NO: 2, wherein the sense strand includes 2?-substituted nucleotides at positions 2, 3, 4 and 13 in the nucleotide sequence shown in SEQ ID NO: 1, the sense strand further includes a 2?-substituted nucleotide(s) at one or more positions selected from the group consisting of positions 12, 14, 17, 18 and 19 in the nucleotide sequence shown in SEQ ID NO: 1, wherein the position 2? of the 2?-substituted nucleotides is —R1, —OR1, —R2OR1, —OR2OR1 or —R3OR2OR1, wherein R1 represents a C1-4 alkyl group, and R2 and R3 independently represent a C1-3 alkylene group.Type: GrantFiled: July 29, 2016Date of Patent: February 4, 2020Assignee: GeneCare Research Institute Co., Ltd.Inventors: Kazunobu Futami, Yasuhiro Furuichi, Satoshi Kaneto
-
Publication number: 20180214574Abstract: Double-stranded modified siRNA targeting a RecQL1 helicase gene includes a sense strand including the nucleotide sequence shown in SEQ ID NO: 1, and an antisense strand including the nucleotide sequence shown in SEQ ID NO: 2, wherein the sense strand includes 2?-substituted nucleotides at positions 2, 3, 4 and 13 in the nucleotide sequence shown in SEQ ID NO: 1, the sense strand further includes a 2?-substituted nucleotide(s) at one or more positions selected from the group consisting of positions 12, 14, 17, 18 and 19 in the nucleotide sequence shown in SEQ ID NO: 1, wherein the position 2? of the 2?-substituted nucleotides is —R1, —OR1, —R2OR1, —OR2OR1 or —R3OR2OR1, wherein R1 represents a C1-4 alkyl group, and R2 and R3 independently represent a C1-3 alkylene group.Type: ApplicationFiled: July 29, 2016Publication date: August 2, 2018Inventors: Kazunobu Futami, Yasuhiro Furuichi, Satoshi Kaneto
-
Patent number: 8809296Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: GrantFiled: September 27, 2012Date of Patent: August 19, 2014Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Publication number: 20140179769Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Patent number: 8703930Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: GrantFiled: May 22, 2013Date of Patent: April 22, 2014Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
CANCER CELL-SPECIFIC APOPTOSIS-INDUCING AGENTS THAT TARGET CHROMOSOME STABILIZATION-ASSOCIATED GENES
Publication number: 20130245097Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: ApplicationFiled: May 22, 2013Publication date: September 19, 2013Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Patent number: 8470798Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: GrantFiled: May 16, 2012Date of Patent: June 25, 2013Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Patent number: 8314073Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.Type: GrantFiled: November 17, 2005Date of Patent: November 20, 2012Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Patent number: 8299044Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: GrantFiled: December 21, 2009Date of Patent: October 30, 2012Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
CANCER CELL-SPECIFIC APOPTOSIS-INDUCING AGENTS THAT TARGET CHROMOSOME STABILIZATION-ASSOCIATED GENES
Publication number: 20120225928Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Applicant: Genecare Research Instiute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Patent number: 8193332Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: GrantFiled: April 8, 2005Date of Patent: June 5, 2012Assignee: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Publication number: 20110033858Abstract: PolydG is added to the terminal overhangs of an siRNA. Next, a primer containing a polydC sequence added with a tag sequence is annealed and cDNA is synthesized by a reverse transcription reaction. Quantitative PCR is performed between a primer carrying the same sequence as the tag sequence, and a primer containing the same sequence as the siRNA sequence to be detected. The amount of siRNA of interest can be determined from a calibration curve produced using known amounts of short-chain dsDNA.Type: ApplicationFiled: January 29, 2009Publication date: February 10, 2011Applicant: GENECARE RESEARCH INSTITUTE CO., LTD.Inventors: Kazunobu Futami, Yasuhiro Furuichi
-
Publication number: 20100168209Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: ApplicationFiled: December 21, 2009Publication date: July 1, 2010Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Publication number: 20090215867Abstract: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered that siRNAs against RecQ1 gene have cancer cell-specific cell proliferation-suppressing effects that are mediated by suppression of the expression of said gene.Type: ApplicationFiled: November 17, 2005Publication date: August 27, 2009Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
Publication number: 20090028861Abstract: The present inventors discovered that inhibition of the expression of various genes associated with chromosome stabilization induces cancer cell-specific apoptosis and inhibits cell proliferation. Compounds that inhibit expression of a gene associated with chromosome stabilization or inhibit the function of a protein encoded by such a gene are thought to have cancer cell-specific apoptosis-inducing effects.Type: ApplicationFiled: April 8, 2005Publication date: January 29, 2009Applicant: Genecare Research Institute Co., Ltd.Inventors: Motoki Takagi, Kazunobu Futami, Akira Shimamoto, Yasuhiro Furuichi -
Patent number: 7329497Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: GrantFiled: May 2, 2006Date of Patent: February 12, 2008Assignee: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Publication number: 20070243570Abstract: The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis.Type: ApplicationFiled: May 19, 2004Publication date: October 18, 2007Applicant: Genecare Research Institute Co., LtdInventors: Motoki Takagi, Akira Shimamoto, Yasuhiro Furuichi, Ayumi Sato
-
Publication number: 20060240470Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: ApplicationFiled: June 30, 2006Publication date: October 26, 2006Applicant: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi
-
Publication number: 20060188928Abstract: The RecQ4 helicase gene, belonging to the RecQ helicase gene family, is revealed herein to be the causative gene of Rothmund-Thomson syndrome. The present inventors found out that it is possible to diagnose Rothmund-Thomson syndrome by detecting mutation of this gene. Further, they uncovered that it is possible to treat patients of Rothmund-Thomson syndrome by utilizing normal RecQ4 helicase gene or proteins thereof.Type: ApplicationFiled: May 2, 2006Publication date: August 24, 2006Applicant: Agene Research Institute Co., Ltd.Inventors: Saori Kitao, Akira Shimamoto, Yasuhiro Furuichi